Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?

WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system

(2010) H.-A. Hou et al.   BLOOD

WHO classification of myeloid neoplasms and leukemia

(2010) H. Wandt et al.   BLOOD

CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice

(2010) M. P. Martelli et al.   BLOOD

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

(2010) S. Abbas et al.   BLOOD

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status

(2010) C. L. Green et al.   BLOOD

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1)

(2010) B. Falini et al.   BLOOD

Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition

(2010) S. M. Leong et al.   BLOOD

Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish

(2010) N. Bolli et al.   BLOOD

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial

(2010) C. Rollig et al.   BLOOD

Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction

(2010) D. C. Taussig et al.   BLOOD

DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

(2010) Maria E. Figueroa et al.   CANCER CELL

Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives

(2010) Brunangelo Falini et al.   CURRENT OPINION IN ONCOLOGY

Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help

(2010) B. Falini et al.   HAEMATOLOGICA

Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms

(2010) T. Ernst et al.   HAEMATOLOGICA

IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication

(2010) Peter Paschka et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance ofCEBPAMutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of DoubleCEBPAMutations and the Interaction WithFLT3andNPM1Mutations

(2010) Claire L. Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Performance and Clinical Evaluation of a Sensitive Multiplex Assay for the Rapid Detection of Common NPM1 Mutations

(2010) Michael Hafez et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Rapid flow cytometric detection of aberrant cytoplasmic localization of nucleophosmin (NPMc) indicating mutant NPM1 gene in acute myeloid leukemia

(2010) U Oelschlaegel et al.   LEUKEMIA

Cytoplasmic Expression of Nucleophosmin Accurately Predicts Mutation in the Nucleophosmin Gene in Patients With Acute Myeloid Leukemia and Normal Karyotype

(2009) Jennifer Luo et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model

(2009) K. Cheng et al.   BLOOD

Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias

(2009) H. B. Ommen et al.   BLOOD

The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication

(2009) J. B. Micol et al.   BLOOD

The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication

(2009) A. Renneville et al.   BLOOD

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features

(2009) C. Haferlach et al.   BLOOD

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML

(2009) S. Schnittger et al.   BLOOD

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)

(2009) F. Schneider et al.   BLOOD

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

(2009) B. J. Wouters et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis

(2009) T Pabst et al.   BRITISH JOURNAL OF CANCER

Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis

(2009) Sergej Konoplev et al.   CANCER

Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?

(2009) G. Mattsson et al.   HAEMATOLOGICA

Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity

(2009) Rachel Rau et al.   HEMATOLOGICAL ONCOLOGY

Favorable Prognostic Impact ofNPM1Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

(2009) Heiko Becker et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome

(2009) Annika Dufour et al.   JOURNAL OF CLINICAL ONCOLOGY

Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications

(2009) B Falini et al.   LEUKEMIA

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse

(2008) P. Sportoletti et al.   BLOOD

MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia

(2008) M. Jongen-Lavrencic et al.   BLOOD

Monitoring minimal residual disease in acute myeloid leukaemia withNPM1mutations by quantitative PCR: clonal evolution is a limiting factor

(2008) Christina Papadaki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): Comparison with WT1 gene expression

(2008) Eva Barragan et al.   CLINICA CHIMICA ACTA

Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability

(2008) G. Meloni et al.   HAEMATOLOGICA

NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia

(2008) B. Falini et al.   HAEMATOLOGICA

Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice

(2008) B. Falini et al.   HAEMATOLOGICA

Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm

(2008) F. Facchetti et al.   HAEMATOLOGICA

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B

(2008) R. F. Schlenk et al.   HAEMATOLOGICA

Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7γ

(2008) Paola Bonetti et al.   JOURNAL OF CELL BIOLOGY

Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group

(2008) Thomas Büchner et al.   JOURNAL OF CLINICAL ONCOLOGY

Nucleophosmin (NPM1) Mutations in Acute Myeloid Leukemia: An Ongoing (Cytoplasmic) Tale of Dueling Mutations and Duality of Molecular Genetic Testing Methodologies

(2008) Gerald Wertheim et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features

(2008) M T Andersen et al.   LEUKEMIA

Therapy-related acute myeloid leukaemia with mutated NPM1: treatment induced or de novo in origin?

(2008) B Falini   LEUKEMIA

A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin and ARF

(2008) N Bolli et al.   LEUKEMIA

Cooperating gene mutations in acute myeloid leukemia: a review of the literature

(2008) A Renneville et al.   LEUKEMIA

Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML

(2008) I H I M Hollink et al.   LEUKEMIA

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

(2008) Timothy J. Ley et al.   NATURE

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin

(2008) R. Garzon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA